评估α-半乳糖神经酰胺脉冲树突状细胞辅助免疫治疗完全切除的II-IIIA期非小细胞肺癌的随机II期研究:随机对照试验研究方案
本研究为随机对照II期试验方案,纳入完全切除后接受顺铂联合长春瑞滨辅助化疗的II-IIIA期非小细胞肺癌患者56例,随机分为α-GalCer脉冲树突状细胞免疫治疗组或标准治疗组,主要终点为无复发生存期,次要终点包括自然杀伤T细胞特异性免疫应答、毒性频率与安全性及总生存期。
要点
- α-GalCer脉冲树突状细胞疗法毒性被认为可忽略,联合术后辅助化疗预期可提高疗效并延长生存。
- 研究纳入完全切除的II-IIIA期非小细胞肺癌患者56例,随机接受α-GalCer脉冲树突状细胞免疫治疗或标准治疗。
- 主要终点为无复发生存期,次要终点为自然杀伤T细胞特异性免疫应答、毒性频率与安全性及总生存期。
核心结论
- 为确定α-GalCer脉冲树突状细胞疗法的疗效,本研究比较完全手术切除后接受顺铂联合长春瑞滨辅助治疗的II-III期非小细胞肺癌患者与未接受额外治疗(仅手术切除加术后辅助化疗)的患者。
研究设计与样本
- 随机对照II期试验方案,计划纳入完全切除的非小细胞肺癌并接受顺铂联合长春瑞滨双药辅助化疗后符合纳入标准的患者56例,随机分配至α-GalCer脉冲树突状细胞免疫治疗组或标准治疗组。
- 试验注册号UMIN000010386(R000012145),注册日期2013年4月1日。
主要发现
- 原文未报告研究结果,本文为研究方案。
关键数值与推荐
- 主要终点为无复发生存期。
- 次要终点为自然杀伤T细胞特异性免疫应答、毒性频率与安全性及总生存期。
- 计划纳入患者总数为56例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: As the toxicity associated with the α-GalCer-pulsed dendritic cell (DC) therapy could be considered to be negligible, its addition to postoperative adjuvant chemotherapy would be expected to greatly improve the therapeutic effect, and could result in prolonged survival. The aim of the present study is to compare the therapeutic efficacy of alpha-galactosylceramide-pulsed DC therapy in patients who have undergone a complete resection of stage II-IIIA non-small-cell lung cancer (NSCLC) followed by postoperative adjuvant therapy with cisplatin plus vinorelbine, to that in patients who did not receive additional treatment (surgical resection plus postoperative adjuvant chemotherapy only). METHODS: Subsequent to the complete resection of NSCLC, followed by the administration of cisplatin plus vinorelbine dual-agent combination adjuvant chemotherapy, patients who satisfy the inclusion criteria will be randomly allocated to either the α-GalCer-pulsed DC immune therapy group, or the standard treatment group. In total, 56 patients will be included in the study. The primary endpoint is recurrence-free survival, and the secondary endpoints are natural killer T-cell-specific immune response, the frequency of toxic effects and safety, and overall survival. DISCUSSION: In order to determine the efficacy of α-GalCer-pulsed DC therapy, the present study compares patients with stage II-III NSCLC who underwent complete surgical resection followed by postoperative adjuvant therapy with cisplatin plus vinorelbine, to those who did not receive additional treatment (surgical resection plus postoperative adjuvant chemotherapy only). TRIAL REGISTRATION: UMIN000010386 ( R000012145 ). Registered on 1 April 2013. UMIN-CTR is officially recognized as a registration site which satisfies ICMJE criteria.
引用
- Saka H, Kitagawa C, Ichinose Y, et al. A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II-IIIA non-small cell lung cancer: study protocol for a randomized controlled trial. Trials. 2017. PMID: 28915900. doi:10.1186/s13063-017-2103-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。